Analyst firms · Raymond James · ARCT
Raymond James ARCT price target and rating history
Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care
Raymond James rates Arcturus Therapeutics Holdings Inc. (ARCT) Underperform, as of its latest action on Aug 10, 2022. It has published 3 rating actions on ARCT since August 2021, including 1 upgrade and 2 downgrades. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.
- Current rating
- Underperform
- Price target
- Not stated
- Median target, all firms
- $20
- Actions on ARCT
- 3
Every Raymond James rating on ARCT
- Aug 10, 2022
- Jan 31, 2022
- Aug 12, 2021
How other firms rate ARCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $20 | Sep 24, 2026 |
| B. Riley Securities | Buy | $22 | Mar 18, 2026 |
| Roth Capital | Buy | $20 | Jan 23, 2026 |
Questions about Raymond James and ARCT
- What is Raymond James's rating on ARCT?
- Raymond James rates ARCT Underperform, a bearish rating, as of Aug 10, 2022.
- When did Raymond James last change its view on ARCT?
- On Aug 10, 2022, Raymond James downgrades to Underperform from Mkt Perform.
- How does Raymond James's ARCT target compare with other analysts?
- Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.
More ARCT rating histories
All Raymond James ratingsARCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.